TNFRSF9 and neoplasm: One major question related to immunotherapy using anti-4-1BB agonistic antibodies is whether their primary site of action is the tumor tissue itself, where they amplify tumor antigen-reactive T cells, or if their effects are mainly observed in the tumor-draining lymph nodes, where they enhance the activation of newly encountered T cells in the presence of tumor antigen-loaded dendritic cells.